Additionally, authors should consider the following when developing the abstract:
- Test compounds utilized in the study should be identified in the abstract as much as possible. In cases where the length of the proper chemical name precludes its use, a manufacturer’s identification number, etc., may be acceptable, provided the structure and chemical identity of the compound are included in the presentation. Abstracts may not be accepted if the authors are unable to disclose the chemical identity of the compound(s) used in the study. It is very common for Poster Session Chairs to present a poster in the session that they are chairing; this is why SOT assigns two Chairs per Poster Session. You may split the poster Chair duties with the other Chair. If the other Chair also is presenting posters during your Poster Session, you are authorized to leave your poster for a few minutes during the session to fulfill the Chair duties as explained in the Poster Session Chair Guidelines.
- It can be challenging to describe results of “big data” studies within the confines of a 4,500-character abstract. Instead, include specific examples of findings to help meet the requirement for description of data.
- All animal experimentation must be carried out in accordance with the Society’s Guiding Principles in the Use of Animals in Toxicology.
- All abstracts submitted with human testing require that IRB protocol has been followed and approval obtained. References are not required in the body of the abstract, but the Scientific Program Committee may request authors to provide the IRB protocol followed.